Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03355157
Title A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - PADMA Study). (PADMA)
Recruitment Recruiting
Gender both
Phase FDA approved
Variant Requirements No
Sponsors German Breast Group
Indications

Her2-receptor negative breast cancer

Therapies

Exemestane + Palbociclib

Tamoxifen

Paclitaxel

Exemestane

Capecitabine

Palbociclib + Tamoxifen

Epirubicin

Vinorelbine

Fulvestrant + Palbociclib

Fulvestrant

Letrozole

Letrozole + Palbociclib

Age Groups: senior | adult
Covered Countries


No variant requirements are available.